HC Deb 08 September 2004 vol 424 c1279W
Mr. Burns

To ask the Secretary of State for Health (1) what proportion of Alzheimer's patients have access to acetylcholinesterase inhibitors on the NHS; [186432]

(2) what progress he is making with plans for all Alzheimer's patients to have access to acetylcholinesterase inhibitors on the NHS; and when he expects access on the NHS to be available for all. [186434]

Dr. Ladyman

Information on the proportion of Alzheimer's patients having access to anti-dementia drugs is not available. In January 2001, the National Institute for Clinical Excellence recommended that the acetylcholinesterase inhibitors, donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl) should be made available on the national health service as one component of the management of those people with mild to moderate Alzheimer's disease.

Back to
Forward to